Moderna starts study of Omicron-specific Covid-19 vaccine booster

27/1/2022 2:01:00 AM

Moderna starts study of Omicron-specific Covid-19 vaccine booster

https://str.sg/wd4TNEW YORK (BLOOMBERG) - Moderna Inc enrolled the first participant in a clinical trial of its Omicron-specific Covid-19 vaccine booster, another step toward fighting thehighly transmissible variantthat's spread around the world in a matter of weeks.

Moderna and rival Pfizer Inc are each rushing to test Omicron-specific vaccines in case they are needed as the variant continues to pummel the globe.Moderna's statement on the new trial comes just one day after Pfizer said it had began aThe Moderna study will test an Omicron-specific booster called mRNA-1273.529 in 600 adults who have received its existing vaccine, including 300 who have received just two doses and another 300 who have also received a third booster shot.

Read more: ST Foreign Desk »

48-year-old man found dead after early morning fire in Jurong East flat

A fire in a flat at Block 236 Jurong East Street 21 left one person dead early Tuesday morning (Aug 16). Read more at stomp.straitstimes.com Read more >>

Pfizer and BioNTech launch trial of Omicron-targeted COVID-19 vaccineNEW YORK: Pfizer and BioNTech said on Tuesday (Jan 25) they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. The companies plan to test the

Pfizer and BioNTech launch trial of Omicron-targeted Covid-19 vaccineOmicron targeted vaccine by Pfizer ScottMorrisonMP GregHuntMP BradHazzard ChrisMinnsMP

Pfizer and BioNTech launch trial of Omicron-targeted Covid-19 vaccineNEW YORK - Pfizer Inc and BioNTech SE said on Tuesday (Jan 25) they started a clinical trial to test a new version of their vaccine specifically designed to target the Covid-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. Banking on volunteers in the United States, the companies plan to test...

Covid-19 variant Omicron can survive up to 21 hours on skin: Study

COVID-19 is less severe with Omicron than Delta, US study suggestsThe Omicron variant appears to result in less severe COVID-19 than seen during previous periods of high coronavirus transmission including the Delta wave, with shorter hospital stays, less need for intensive care and fewer deaths, according to a new US study. However, the fast-spreading Omicron varian Shocker LOL. Why sugarcoat? Scientific data shows Omicron is actually milder than Flu! It doesn’t replicate well in lungs or cause loss of taste & smell.💁‍♂️ But of cose, some vested interests still wanna fearmonger yall with high numbers to take endless boosters. Smh.

South Korea's daily Covid-19 count tops 8,000 for first time amid Omicron spreadSEOUL — South Korea's daily count of new coronavirus cases topped 8,000 for the first time on Tuesday (Jan 25), as the highly contagious Omicron variant spreads rapidly despite the recent extension of strict social-distancing rules to slow infection.

Copy to clipboard https://str.LinkedIn NEW YORK: Pfizer and BioNTech said on Tuesday (Jan 25) they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.Copy to clipboard https://str.Reuters Screengrab/YouTube/Reuters NEW YORK - Pfizer Inc and BioNTech SE said on Tuesday (Jan 25) they started a clinical trial to test a new version of their vaccine specifically designed to target the Covid-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen.

sg/wd4T NEW YORK (BLOOMBERG) - Moderna Inc enrolled the first participant in a clinical trial of its Omicron-specific Covid-19 vaccine booster, another step toward fighting the highly transmissible variant that's spread around the world in a matter of weeks. Moderna and rival Pfizer Inc are each rushing to test Omicron-specific vaccines in case they are needed as the variant continues to pummel the globe. They are also testing a fourth dose of the current vaccine against a fourth dose of the Omicron-based vaccine in people who received their third dose of the Pfizer-BioNTech vaccine three to six months earlier. Moderna's statement on the new trial comes just one day after Pfizer said it had began a The Moderna study will test an Omicron-specific booster called mRNA-1273. They are also testing a fourth dose of the current vaccine against a fourth dose of the Omicron-based vaccine in people who received a third dose of the Pfizer/BioNTech vaccine three to six months earlier.529 in 600 adults who have received its existing vaccine, including 300 who have received just two doses and another 300 who have also received a third booster shot. "While current research and real-world data show that boosters continue to provide a high level of protection against severe disease and hospitalisation with Omicron, we recognise the need to be prepared in the event this protection wanes over time and to potentially help address Omicron and new variants in the future," Pfizer's head of vaccine research and development, Kathrin Jansen, said in a statement. The trial will examine both the safety and the immune response generated by the Omicron-specific shot. Depending on the amount of clinical trial data required by regulators, it may not be possible to realise a current plan to launch an Omicron-targeting vaccine by the end of March, BioNTech said.

Vaccine makers are grappling with what kinds of shots may be most effective as the coronavirus continues to mutate. Still, the US Centers for Disease Control and Prevention says a third dose of an mRNA vaccine like the Pfizer-BioNTech vaccine has provided 90 per cent protection against hospitalisation due to COVID-19. Depending on the amount of clinical trial data required by regulators, it may not be possible to realise a current plan to launch an Omicron-targeting vaccine by the end of March, BioNTech said. Omicron-specific boosters are one possibility; another is a multivalent vaccine that would induce protection against multiple strains. Other strategies include broad-acting vaccines that would work against even more mutations. BioNTech Chief Executive Ugur Sahin told Reuters in November that regulators would not likely require testing of an Omicron-based vaccine on humans because it and Pfizer had already created versions of their established vaccine to target the earlier Alpha and Delta variants, with clinical trials continuing. Moderna is testing the Omicron-targeted booster because of"the long-term threat demonstrated by Omicron's immune escape," Chief Executive Officer Stephane Bancel said in the statement. Some countries have already started offering additional booster doses, but a recent study from Israel showed that while a fourth dose of an mRNA vaccine boosted antibodies, the level was not high enough to prevent infection by the Omicron variant. "We are also evaluating whether to include this Omicron-specific candidate in our multivalent booster programme. These studies should show that neutralising antibodies in the blood of participants are superior to those elicited by current vaccines. EMA said these studies should show that the new vaccines elicit more neutralising antibodies in the blood than current vaccines and might also protect against new variants of concern.

" In the same statement, the company said it was reassured by a report in the New England Journal of Medicine showing that patients who had received three doses of Moderna's existing vaccine still had neutralising antibodies against Omicron six months after the third shot. However, after the booster, levels of Omicron-fighting antibodies declined faster than those against the original virus strain. The Omicron variant has replaced the Delta variant as the dominant lineage in many parts of the world and Omicron itself is now splitting into different subforms, one of which, BA2, is causing particular concern. These studies should show that neutralising antibodies in the blood of participants are superior to those elicited by current vaccines. More On This Topic .